The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease (Q48670660)

14 February 2018

title

The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease (English)

1 reference

14 February 2018

0 references

0 references

1 reference

Sebastiaan Engelborghs

series ordinal

1

object named as

Sebastiaan Engelborghs

1 reference

14 February 2018

author name string

Nathalie Le Bastard

series ordinal

2

1 reference

14 February 2018

publication date

1 June 2012

1 reference

14 February 2018

Molecular Diagnosis and Therapy

published in

1 reference

14 February 2018

volume

16

1 reference

14 February 2018

issue

3

1 reference

14 February 2018

page(s)

135-141

1 reference

14 February 2018

Stopping a thief and killer: Alzheimer's disease crisis demands greater commitment to research

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Added diagnostic value of CSF biomarkers in differential dementia diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Multiprotein deposits in neurodegenerative disorders: our experience in the tissue brain bank of Navarra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Differences in neuropathologic characteristics across the Lewy body dementia spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Prevalence of small cerebral bleeds in patients with a neurodegenerative dementia: a neuropathological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

CSF biomarkers in relationship to cognitive profiles in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Dementia: Alzheimer pathology and vascular factors: from mutually exclusive to interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid Peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262201

Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group

21 January 2018

1 reference

12 December 2020

Differences and Similarities between Two Frequently Used Assays for Amyloid 42 in Cerebrospinal Fluid

1 reference

12 December 2020

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

1 reference

12 December 2020

Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease

1 reference

12 December 2020

Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes

1 reference

12 December 2020

2011 Alzheimer's disease facts and figures

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03262201

1 reference

14 February 2018

release_5wcvoa6obfhmpglljd7n6wqbmq

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5wcvoa6obfhmpglljd7n6wqbmq

24 November 2022

mapped directly with Wikidata item

1 reference

14 February 2018